CA3123610A1 - Analogs that target mitochondrial diseases - Google Patents

Analogs that target mitochondrial diseases Download PDF

Info

Publication number
CA3123610A1
CA3123610A1 CA3123610A CA3123610A CA3123610A1 CA 3123610 A1 CA3123610 A1 CA 3123610A1 CA 3123610 A CA3123610 A CA 3123610A CA 3123610 A CA3123610 A CA 3123610A CA 3123610 A1 CA3123610 A1 CA 3123610A1
Authority
CA
Canada
Prior art keywords
h2nynh
compound
õr3b
h2nr
njl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3123610A
Other languages
English (en)
French (fr)
Inventor
Guozhu ZHENG
Mark J. BAMBERGER
Inese Smukste
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Biotherapeutics Inc
Original Assignee
Stealth Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Corp filed Critical Stealth Biotherapeutics Corp
Publication of CA3123610A1 publication Critical patent/CA3123610A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3123610A 2018-12-18 2019-11-19 Analogs that target mitochondrial diseases Pending CA3123610A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862781156P 2018-12-18 2018-12-18
US62/781,156 2018-12-18
PCT/US2019/062284 WO2020131283A1 (en) 2018-12-18 2019-11-19 Analogs that target mitochondrial diseases

Publications (1)

Publication Number Publication Date
CA3123610A1 true CA3123610A1 (en) 2020-06-25

Family

ID=71101584

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3123610A Pending CA3123610A1 (en) 2018-12-18 2019-11-19 Analogs that target mitochondrial diseases

Country Status (9)

Country Link
US (2) US12252554B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898653A4 (cg-RX-API-DMAC7.html)
JP (1) JP7606966B2 (cg-RX-API-DMAC7.html)
KR (1) KR102995415B1 (cg-RX-API-DMAC7.html)
CN (1) CN113383005A (cg-RX-API-DMAC7.html)
AU (1) AU2019401254B2 (cg-RX-API-DMAC7.html)
CA (1) CA3123610A1 (cg-RX-API-DMAC7.html)
IL (1) IL284014A (cg-RX-API-DMAC7.html)
WO (1) WO2020131283A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113544138B (zh) 2018-12-18 2024-10-29 隐形生物治疗公司 线粒体靶向肽
WO2020131283A1 (en) 2018-12-18 2020-06-25 Stealth Biotherapeutics Corp. Analogs that target mitochondrial diseases
US20240197623A1 (en) * 2021-04-07 2024-06-20 Stealth Bio Therapeutics Inc. Silica-based formulations of therapeutic oliogpeptides and peptidomimetics
KR102876070B1 (ko) * 2023-02-08 2025-10-24 웰펩 주식회사 신규 펩티도미메틱을 유효성분으로 포함하는 아토피 피부염의 예방 또는 치료용 조성물
WO2026151834A1 (en) 2025-01-09 2026-07-16 Stealth Biotherapeutics Inc. Compounds for use in medical management of subjects with muscular dystrophy
WO2026151846A1 (en) 2025-01-09 2026-07-16 Stealth Biotherapeutics Inc. Compositions for use in the treatment of heart failure, idiopathic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, hypertrophic cardiomyopathy, or hypertensive cardiomyopathy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
CA2787331A1 (en) * 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
EP2808029A3 (en) 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
CN103249423A (zh) 2010-07-09 2013-08-14 康肽德生物医药技术有限公司 预防或治疗缺血/再灌注损伤之后无复流的方法
US8383919B2 (en) 2010-12-14 2013-02-26 Xueyun Gao Highly fluorescent peptide-metallic nanoclusters as bio-probes and methods of synthesis thereof
EP3108975A1 (en) 2011-03-24 2016-12-28 Cornell University Aromatic-cationic peptides and uses of same
CA2865409C (en) 2012-02-23 2020-07-21 Cornell University Aromatic-cationic peptides and uses of same
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CA2916492A1 (en) 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
CN106459169A (zh) 2014-03-03 2017-02-22 康德生物医疗技术公司 药学上相关的芳香族阳离子肽
WO2015183984A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
WO2016144352A2 (en) 2015-03-11 2016-09-15 Stealth Peptides International, Inc. Therapeutic compositions including acrylamido compounds or phenyl-substituted maleimide compounds, variants thereof and methods of using the same
WO2017093897A1 (en) 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CA3010321A1 (en) 2015-12-31 2017-07-06 Scott Duncan Therapeutic compositions including peptides and uses thereof
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
US20190276494A1 (en) 2016-05-19 2019-09-12 Stealth Biotherapeutics Corp. Compositions and methods for the prevention and treatment of mitochondrial myopathies
WO2018186404A1 (ja) * 2017-04-03 2018-10-11 出光興産株式会社 有機エレクトロルミネッセンス素子及び電子機器
WO2018223032A1 (en) 2017-06-02 2018-12-06 Stealth Biotherapeutics Corp. Crystalline salt forms of sbt-20
US20200361987A1 (en) 2017-11-15 2020-11-19 Stealth Biotherapeutics Corp. Deuterated tetrapeptides that target mitochondria
CN113544138B (zh) 2018-12-18 2024-10-29 隐形生物治疗公司 线粒体靶向肽
WO2020131283A1 (en) 2018-12-18 2020-06-25 Stealth Biotherapeutics Corp. Analogs that target mitochondrial diseases

Also Published As

Publication number Publication date
CN113383005A (zh) 2021-09-10
AU2019401254A1 (en) 2021-06-24
WO2020131283A1 (en) 2020-06-25
EP3898653A1 (en) 2021-10-27
KR20210093958A (ko) 2021-07-28
US20220041654A1 (en) 2022-02-10
AU2019401254B2 (en) 2025-05-01
KR102995415B1 (ko) 2026-07-23
US20260008810A1 (en) 2026-01-08
US12252554B2 (en) 2025-03-18
JP7606966B2 (ja) 2024-12-26
EP3898653A4 (en) 2022-08-24
JP2022514241A (ja) 2022-02-10
IL284014A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
US20260008810A1 (en) Analogs that target mitochondrial diseases
US20240092832A1 (en) Deuterated tetrapeptides that target mitochondria
US20260055136A1 (en) Mitochondria-targeting peptides
US20080194489A1 (en) Treatment of iatrogenic disease
US20080242837A1 (en) Peptide compositions
IL300697A (en) Mitochondria-targeted peptides
JP2002521386A (ja) ウロキナーゼおよび血管形成のインヒビター
US5338725A (en) Anti-aggregatory agents for platelets
WO2021262710A1 (en) Prodrugs of mitochodria-targeting oligopeptides
US11795196B2 (en) Mitochondria-targeting peptides
US20230227499A1 (en) Prodrugs of mitochondria-targeting oligopeptides
WO2022183360A1 (en) Short synthetic peptide and their uses for treating dry eye disease
EP2279743A2 (en) ApoE mimetic agents

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240729

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250130

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250214

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250214

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250430

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250430

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250605

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251003

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251114

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251127

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251205

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251205

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260613

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260615